Back

Structure Therapeutics reports up to 16.2% weight loss in oral-drug trials

Verifying
  • Structure Therapeutics reported clinical findings for ACCG-2671 and aleniglipron.
  • A 180 mg aleniglipron dose produced up to 16.2% weight loss after 72 weeks.
  • Structure Therapeutics began a multiple ascending dose trial with data expected in early 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.